Sun Pharma, Cipla and others partner to carry out trials of COVID-19 antiviral drug Molnupiravir

According to the regulation of the Subject Professional Committee (SEC) of the Central Drugs Standard Control Organization, Dr.Reddy’s will conduct the clinical trial using its item, and the other 4 pharma companies will be needed to demonstrate equivalence of their item to the product utilized by Dr. Reddy’s in its scientific trial.

Molnupiravir Demonstrated Highly Promising Results In Reducing Viral Load To Almost Zero In Merely 5 Days Of Treatment Duration. (Representative Image)

< img class=" MC_img" src="" data-src="" alt =" Molnupiravir showed extremely appealing results in minimizing viral load to almost zero in simply 5 days of treatment period. (Agent image)

” title= “Molnupiravir demonstrated extremely promising lead to reducing viral load to nearly absolutely no in merely 5 days of treatment period.( Representative image)” width=” 100 %” height=” auto”/ > Molnupiravir demonstrated extremely promising outcomes in lowering viral load to nearly no in simply 5 days of treatment period.( Representative image) In a very first of kind its initiative, five big Indian pharmaceutical business Cipla, Dr Reddy’s, Emcure, Sun Pharma and Torrent Pharma have actually signed up with hands to carry out medical trials of COVID-19 oral antiviral drug Molnupiravir for the treatment of moderate COVID-19 in an outpatient setting in India.

As per the instruction of the Topic Specialist Committee (SEC) of the Central Drugs Requirement Control Organization, Dr.Reddy’s will perform the scientific trial using its item, and the other 4 pharma business will be required to show equivalence of their product to the product utilized by Dr. Reddy’s in its scientific trial.

The parties will collectively sponsor, supervise and keep track of the scientific trial in India.

Following the scientific trial protocol approval provided by the Drugs Controller General of India, the medical trial will be conducted for the treatment of mild COVID-19 in an outpatient setting. It is anticipated to happen in between June and September this year across India with the recruitment of 1,200 clients.

Between March and April this year, these five pharma business had separately participated in a non-exclusive voluntary licensing contract with Merck Sharpe Dohme (MSD) to produce and provide Molnupiravir to India and over 100 low and middle-income nations (LMICs).

” Such cooperation for a clinical trial is a first of its kind within the Indian

pharma market, and will aim to investigate yet another line of treatment in the cumulative battle against the COVID-19 pandemic,” the 5 companies stated in a joint statement.

On effective completion of the medical trial, each business will independently approach the regulative authorities for approval to produce and supply Molnupiravir for the treatment of COVID-19 in India.

Molnupiravir is an oral anti-viral that inhibits the duplication of numerous RNA infections consisting of SARS-CoV-2.

It is currently being studied by MSD (Called as Merck in United States), through a collaboration with Ridgeback Biotherapeutics, in a Phase III trial for the treatment of non-hospitalized patients with confirmed COVID-19 internationally.


Viswanath Pilla is a business reporter with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, health care and infrastructure sectors for Moneycontrol.

Released at Tue, 29 Jun 2021 11:18:56 +0000